Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2

NCT07531979 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

93

Enrollment

OTHER

Sponsor class

Conditions

ESCC
Tislelizumab
Chemotherapy
Becotatug Vedotin
EGFR ADC
PD-1 Inhibitor

Interventions

DRUG: Tislelizumab
DRUG: Becotatug Vedotin
DRUG: Cisplatin
DRUG: Tislelizumab
DRUG: Becotatug Vedotin
DRUG: Cisplatin

Sponsor

Tianjin Medical University Cancer Institute and Hospital